retatrutide clinical trials us Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation found. @adamyamaguchi Lilly's triple agonist achieves 16.8%

Whether Phase 3 confirms those numbers at scale is the question that will define retatrutides future

Eli Lilly and Company (2021) Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential

Some orthopedic surgeons may perceive the growing use of GLP-1 receptor agonists as a potential threat to their practice, fearing that widespread weight loss could reduce the volume of patients requiring joint replacements

Gastrointestinal symptoms and occasional psychiatric concerns require monitoring

LaFata et al., 2025) and such a pattern of food-intake behavior closely mirrors the compulsive consumption observed in drug addiction, where people are unable to abstain or moderate usage despite recognizing the associated risks (DSM-V, 2013)